Ultragenyx Pharma Is Maintained at Overweight by Morgan Stanley
Ultragenyx Pharmaceutical Analyst Ratings
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Morgan Stanley Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $65
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $39 to $110
Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference
Ultragenyx Pharmaceutical | 10-Q: Q1 2025 Earnings Report
Express News | Ultragenyx Pharmaceutical Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results
Truist Financial Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Express News | Ultragenyx Pharmaceutical Inc : Truist Securities Cuts Target Price to $100 From $140
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $86
Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating
Earnings Call Summary | Ultragenyx Pharmaceutical(RARE.US) Q1 2025 Earnings Conference
Ultragenyx Pharmaceutical Q1 Loss Narrows
Ultragenyx Pharmaceutical | 8-K: Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
Ultragenyx Pharmaceutical GAAP EPS of -$1.57 Beats by $0.08, Revenue of $139M Misses by $5.46M
Earnings Flash (RARE) Ultragenyx Pharmaceutical Reports Q1 Revenue $139.3M, Vs. FactSet Est of $143.8M
Express News | Ultragenyx Pharmaceutical Affirms FY2025 Sales Guidance of $640.00M-$670.00M Vs $655.02M Est
Express News | Ultragenyx Q1 Net Income USD -151 Million
Press Release: Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update